Lipum Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Ola Sandborgh

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	2.9yrs

Recent management updates

Recent updates

CEO

Ola Sandborgh (57 yo)

less than a year

Tenure

Mr. Ola Sandborgh serves as CEO at Lipum AB (publ) since December 01, 2023. He has experience from the pharmaceutical industry where he has worked in leading roles in different commercial, innovation and b...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Olle Hernell	Co-Founder & Director	no data	kr303.50k	1.51% SEK 2.2m
Marina Norberg	Chief Financial Officer	3.3yrs	kr553.50k	0.037% SEK 54.6k
Ola Sandborgh	Chief Executive Officer	less than a year	no data	no data
Susanne Lindquist	Co-Founder & Head of Research (CSO)	no data	no data	1.47% SEK 2.2m
Pernilla Abrahamsson	Chief Operating Officer	no data	no data	0.014% SEK 21.0k
Karin Franck-Larsson	C.M.O.	less than a year	no data	no data

0.5yrs

Average Tenure

59yo

Average Age

Experienced Management: LIPUM's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Olle Hernell	Co-Founder & Director	no data	kr303.50k	1.51% SEK 2.2m
Ulf Bjorklund	Independent Chairman of the Board	no data	no data	0.063% SEK 94.1k
Björn Löwenadler	Member of Scientific Advisory Board	no data	no data	no data
Carl-Johan Spak	Independent Director	less than a year	no data	no data
Anders Fasth	Member of Scientific Advisory Board	no data	no data	no data
Lennart Lundberg	Member of Scientific Advisory Board	2.8yrs	no data	no data
Asa Hansdotter	Independent Director	2.9yrs	no data	no data
Ingemar Kihlstrom	Independent Director	2.9yrs	no data	no data
Kristian Sandberg	Independent Director	4.2yrs	no data	no data
Rikard Holmdahl	Member of Scientific Advisory Board	no data	no data	no data
Solbritt Dahlqvist	Member of Scientific Advisory Board	no data	no data	no data

2.9yrs

Average Tenure

68.5yo

Average Age

Experienced Board: LIPUM's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.

Lipum Management

Management criteria checks 0/4

Key information

Recent management updates

Lipum AB (publ) Announces Nomination Committee Appointments

Lipum AB (Publ) Appoints Ola Sandborgh as Chief Executive Officer, Effective from December 1, 2023

Lipum AB (Publ) Appoints Karin Franck-Larsson as CMO

Lipum Elects Carl-Johan Spak as New Board Member

Chief Executive Officer recently bought kr161k worth of stock

Lipum AB (publ) Announces the Nomination Committee for the 2023 Annual General Meeting

Recent updates

Lipum AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 79.714945 million.

Lipum Recommends Shareholders to Not Accept Mandatory Cash Offer

Lipum Recommends Shareholders to Not Accept Mandatory Cash Offer

Forecast to breakeven in 2025

Lipum AB (publ) has filed a Follow-on Equity Offering.

Lipum AB (publ) has filed a Follow-on Equity Offering.

Lipum AB (publ) Reports Positive Interim Results from Clinical Phase 1 Study Showing that SOL-116 Reduces Plasma BSSL Levels in Healthy Subjects

Lipum AB (Publ) Receives Funding from Vinnova for an Eurostars Application

Lipum AB (publ) Announces Nomination Committee Appointments

Lipum AB (Publ) Appoints Ola Sandborgh as Chief Executive Officer, Effective from December 1, 2023

New major risk - Revenue and earnings growth

Lipum AB (Publ) Appoints Karin Franck-Larsson as CMO

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Lipum Elects Carl-Johan Spak as New Board Member

Chief Executive Officer recently bought kr161k worth of stock

Lipum AB (publ) Announces the Nomination Committee for the 2023 Annual General Meeting

Chief Executive Officer recently bought kr157k worth of stock

Lipum AB (Publ) Has Initiated A Phase 1 Clinical Study with Its Drug Candidate Sol-116

Lipum AB (publ) announced that it has received SEK 38.999963 million in funding from Flerie Invest AB

Lipum AB (publ) Gets Approval to Start Phase 1 Clinical Trial with Drug Candidate Sol-116

Lipum AB (publ) Appoints Helena Bergström as Chief Medical Officer

Lipum Reports Completion of GLP Toxicology- and Safety Program on the Candidate Drug (SOL-116)

Chief Executive Officer recently bought kr195k worth of stock

Lipum AB (Publ) Reports Gmp Production of Sol-116 Successful

Lipum Recruits Fredrik Seijsing as Scientist

Lipum AB (publ) Initiates GMP-Production for Clinical Trials

Lipum Is At the Final Step Before Clinical Phase

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age